Informatie:
Fout:
ID
22516
Beschrijving
Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00199537
Link
https://clinicaltrials.gov/show/NCT00199537
Trefwoorden
Versies (1)
- 06-06-17 06-06-17 -
Geüploaded op
6 juni 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Prostate Cancer NCT00199537
Eligibility Prostate Cancer NCT00199537
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00199537
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Gender
Item
men
boolean
C0079399 (UMLS CUI [1])
Age
Item
age of 40 years or greater
boolean
C0001779 (UMLS CUI [1])
Prostate carcinoma Advanced | Prostate specific antigen measurement | LHRH
Item
diagnosis of advanced prostate cancer (ie: prostate-specific antigen [psa] less than 25 ug/l and undergoing continued treatment with leuteinizing hormone-releasing hormone [lhrh] therapy)
boolean
C0600139 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2])
C0023610 (UMLS CUI [3])
C0205179 (UMLS CUI [1,2])
C0201544 (UMLS CUI [2])
C0023610 (UMLS CUI [3])
Informed Consent
Item
willing and able to consent
boolean
C0021430 (UMLS CUI [1])
Secondary malignant neoplasm of bone
Item
metastatic disease to bone
boolean
C0153690 (UMLS CUI [1])
Pharmaceutical Preparations Affecting Bone remodeling | Diphosphonates | Steroids | Anticonvulsants
Item
medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant)
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0085268 (UMLS CUI [1,3])
C0012544 (UMLS CUI [2])
C0038317 (UMLS CUI [3])
C0003286 (UMLS CUI [4])
C0392760 (UMLS CUI [1,2])
C0085268 (UMLS CUI [1,3])
C0012544 (UMLS CUI [2])
C0038317 (UMLS CUI [3])
C0003286 (UMLS CUI [4])
Kidney Failure | Creatinine measurement, serum
Item
renal failure (serum creatinine > 200 umol/l)
boolean
C0035078 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C0201976 (UMLS CUI [2])
Comorbidity Affecting Bone Density | Paget's Disease | Rheumatoid Arthritis
Item
co-morbidity factors affecting bone density (ie: paget's, rheumatoid arthritis)
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0005938 (UMLS CUI [1,3])
C1368019 (UMLS CUI [2])
C0003873 (UMLS CUI [3])
C0392760 (UMLS CUI [1,2])
C0005938 (UMLS CUI [1,3])
C1368019 (UMLS CUI [2])
C0003873 (UMLS CUI [3])
Factor Affecting Bone Density Test | Head of femur Measurement | Arthroplasty of hip, bilateral
Item
factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty)
boolean
C1521761 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0177804 (UMLS CUI [1,3])
C0015813 (UMLS CUI [2,1])
C0242485 (UMLS CUI [2,2])
C0845633 (UMLS CUI [3])
C0392760 (UMLS CUI [1,2])
C0177804 (UMLS CUI [1,3])
C0015813 (UMLS CUI [2,1])
C0242485 (UMLS CUI [2,2])
C0845633 (UMLS CUI [3])
Malignant Neoplasms | Malignant Neoplasms Affecting research results
Item
cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial
boolean
C0006826 (UMLS CUI [1])
C0006826 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0683954 (UMLS CUI [2,3])
C0006826 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0683954 (UMLS CUI [2,3])
Gastrointestinal Diseases | Malabsorption Syndrome
Item
gastrointestinal (gi) pathology (eg. malabsorption syndrome)
boolean
C0017178 (UMLS CUI [1])
C0024523 (UMLS CUI [2])
C0024523 (UMLS CUI [2])
Parathyroid Diseases
Item
parathyroid disease
boolean
C0030517 (UMLS CUI [1])